Catheter Precision, Inc. Files Form 8-K: New Securities Purchase Agreement with Key Investor Updates
Overview
Catheter Precision, Inc. (“the Company”) has filed a Form 8-K dated June 7, 2026, reporting on a significant transaction involving the sale of common stock. The filing includes a Securities Purchase Agreement and Registration Rights Agreement that lay out the terms under which investors will acquire shares, and how these shares will be handled with respect to regulatory registration and resale. This article highlights the most important aspects of the report, focusing on items that may affect shareholder value and could be price sensitive.
Key Points from the Report
- Common Stock Issuance: The Company is issuing common stock with a par value of \$0.0001 per share, trading on NYSE American. The per share purchase price is set at \$0.34, subject to adjustments for stock splits, dividends, and similar corporate actions.
- Lead Investor: The lead investor for this transaction is Catheter Precision, Inc., indicating strong confidence from internal stakeholders.
- Registration Rights: Purchasers will have registration rights for the shares, meaning the Company is obligated to file and maintain registration statements with the SEC so that investors can resell their shares. The registration statement must remain effective until all shares are either sold or may be sold without restriction under Rule 144.
- Disclosure Commitments: The Company commits to timely public disclosure of material non-public information, including the issuance of a press release and filing of a Current Report on Form 8-K with material transaction terms and exhibits.
- Use of Proceeds: Net proceeds from the sale of these securities are strictly earmarked for working capital purposes. The proceeds cannot be used for debt satisfaction (except for trade payables), redemption of stock or equivalents, litigation settlement, or any activity in violation of FCPA or OFAC regulations.
- Listing Obligations: The Company will use best efforts to maintain the listing of its common stock on NYSE American and ensure the newly issued shares are eligible for electronic transfer via Depository Trust Company.
- Anti-Takeover and Shareholder Rights: The Company affirms that shareholders acquiring securities in this transaction will not trigger any anti-takeover provisions, poison pill arrangements, or similar plans.
- Financial Statements and Controls: The Company asserts it has filed all required SEC reports and that its financial statements comply with GAAP. There are no material undisclosed liabilities or events since the last audited financials.
- Private Placement Status: The transaction is structured as a private placement, not requiring registration under the Securities Act for the initial issuance. Only accredited investors are eligible, and there is no general solicitation involved.
- Material Adverse Effect Clauses: The Company represents that no events have occurred that would reasonably be expected to result in a material adverse effect on its business, operations, or financial condition.
- Tax Compliance: The Company and its subsidiaries are current on all material tax filings and payments, with no known material unpaid taxes.
- Money Laundering and Regulatory Compliance: The Company confirms compliance with all relevant money laundering laws and has not been subject to any action or proceeding under such laws.
- Restriction Removal: Shares issued will not bear restrictive legends under certain conditions, including when registration statements are effective or shares can be sold under Rule 144 without volume or manner-of-sale restrictions.
Potentially Price Sensitive and Shareholder-Relevant Issues
- Capital Raise and Dilution: The issuance of new common stock at \$0.34 per share could lead to dilution for existing shareholders. Investors should consider the impact on earnings per share and overall ownership percentages.
- Regulatory and Disclosure Enhancements: The Company’s commitment to robust registration and public disclosure mechanisms reduces risk for investors seeking liquidity, but also signals management’s intent to maintain transparent operations.
- Use of Proceeds and Financial Health: Restricting proceeds to working capital may support business continuity and growth, but prevents usage for debt reduction or litigation settlement. This could affect the Company’s financial flexibility.
- Anti-Takeover Protections: Assurance that investors will not trigger anti-takeover provisions may encourage institutional participation and reduce risk of hostile corporate actions.
- Listing Maintenance: The Company’s commitment to maintain NYSE American listing and electronic transfer eligibility is critical for investor confidence, liquidity, and share price stability.
- Material Adverse Effect Clauses: The Company’s assertion that no material adverse events have occurred is positive, but investors should monitor for future disclosures that could change this assessment.
- Registration Rights and Liquidity: Investors acquiring these shares have strong registration rights, which could accelerate resale activity and affect trading volumes and price dynamics.
Conclusion
The Form 8-K and accompanying Securities Purchase Agreement mark a significant capital raise and governance update for Catheter Precision, Inc. The detailed provisions regarding registration, disclosure, use of proceeds, and shareholder protections provide investors with enhanced security and transparency. However, the issuance of new common stock at a fixed price may impact share value through dilution, and the Company’s ongoing obligations to maintain listing and regulatory compliance will be closely watched by the market. Investors should monitor subsequent filings and press releases for further updates, especially regarding registration statement effectiveness and any future corporate actions.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The information provided is based on public filings as of June 7, 2026, and may be subject to change.
